IPV Polio Vaccine Side Effects — Post-Market Data

IPV polio vaccine side effects and post-market safety data — documenting adverse event reports and surveillance findings for inactivated poliovirus vaccines used in the United States.

Post-licensure findings on IPOL (Sanofi), the only injectable polio vaccine on the US schedule. The most significant findings concern (1) the CDC's own admission that IPV does not prevent intestinal infection or fecal-oral transmission of poliovirus — undermining the herd immunity rationale for mandatory IPV vaccination; (2) the changing polio diagnostic criteria in 1955 that created a statistical artifact in pre/post-vaccine comparisons; (3) the CDC autism lawsuit, which found zero CDC-cited studies examined IPV in infants; and (4) the Henry Ford vaccinated vs. unvaccinated study which included IPV recipients in the 18,468-child cohort.

CDC Acknowledges IPV Does Not Prevent Transmission

The CDC explicitly acknowledges that IPV (the injected inactivated form) does not prevent intestinal infection or fecal-oral transmission of poliovirus. IPV protects vaccinated individuals against paralytic disease by inducing serum antibodies (IgG) but does not generate mucosal immunity (secretory IgA) in the gut. A vaccinated person can still become infected and shed poliovirus in stool.

This means IPV cannot contribute to herd immunity by preventing transmission — only OPV (the live oral form, no longer used in the US) could do that. The herd immunity argument for IPV mandate thus rests on a transmission-blocking mechanism the vaccine does not possess. See Herd Immunity.

Polio Diagnostic Criteria Change (1955)

The 1955 Salk vaccine rollout coincided with a change in polio diagnostic criteria:

This reclassification alone would have reduced reported polio cases in the post-vaccine era regardless of any vaccine effect. Cases that previously would have been classified as polio (and counted in pre-vaccine statistics) would, after 1955, be reclassified as other conditions (transverse myelitis, Guillain-Barré, aseptic meningitis, "non-paralytic polio," etc.).

This is a confounding variable in any pre/post-vaccine comparison. Leading scientists of the 1960s — including the inventor of the Sabin oral vaccine — publicly questioned the official efficacy data on these grounds. See Polio History and Vaccine Narrative.

Pre-Vaccine Polio Mortality Decline

Pre-vaccine mortality charts from the CDC's own historical records show that polio mortality in the US had already declined by approximately 47% before the Salk vaccine was introduced in 1955. The conventional polio narrative attributes this decline entirely to vaccination — Aaron Siri argues this is selective attribution that ignores the pre-existing trend driven by improved sanitation, nutrition, and medical care. See Polio History and Vaccine Narrative.

Henry Ford Vaccinated vs. Unvaccinated Study

The Henry Ford Vaccinated vs. Unvaccinated Study examined 18,468 children in a birth cohort using electronic medical records, comparing vaccinated and unvaccinated children for chronic disease outcomes. Vaccinated children received IPV (along with the rest of the schedule); unvaccinated children did not. Findings:

Henry Ford Health System administration blocked submission of the study for publication. The research was conducted by mainstream pro-vaccine scientists using the institution's own EMR data. See Henry Ford Vaccinated vs. Unvaccinated Study.

This study cannot isolate IPV-specific effects from the rest of the schedule, but IPV is one of the vaccines administered during the period the study examined.

CDC Autism Lawsuit: IPV Not Studied

In court stipulation responding to ICAN's lawsuit, the CDC identified its complete evidence base for claiming infant vaccines do not cause autism: 20 studies. Upon review, zero of those 20 studies examined IPV in the relevant infant age window for autism causation. See Post-Licensure Safety Monitoring.

VAERS, VSD, V-SAFE Coverage

IPV is nominally subject to post-licensure surveillance through VAERS, VSD (Vaccine Safety Datalink), and V-SAFE. None of these systems has produced regulatory action against IPV despite the package insert's acknowledgment of deaths in temporal association with vaccination (which was reported but never investigated against a control baseline because no control existed).

See Also

IPV Vaccines (Pre-Licensure), Herd Immunity, Polio History and Vaccine Narrative, Henry Ford Vaccinated vs. Unvaccinated Study, Post-Licensure Safety Monitoring

Frequently Asked Questions

Frequently Asked Questions

Can the polio vaccine (IPV) prevent poliovirus transmission?
No. The CDC explicitly acknowledges that IPV does not prevent intestinal infection or fecal-oral transmission of poliovirus. IPV protects vaccinated individuals from paralytic disease by producing blood antibodies but does not generate mucosal immunity in the gut. A vaccinated person can still become infected and shed poliovirus in stool. Only OPV (the live oral form, no longer used in the US) could block transmission.
Did polio cases really drop because of the vaccine?
The relationship is more complex than the standard narrative suggests. Pre-vaccine mortality charts from CDC historical records show polio mortality had already declined by approximately 47% before the Salk vaccine was introduced in 1955. Additionally, the diagnostic criteria for polio were changed in 1955 — paralysis now had to persist for 60 days to be counted as polio, where before any paralysis with poliovirus present qualified. This reclassification alone would have reduced reported cases regardless of vaccine effect.
Has the CDC studied whether the polio vaccine causes autism?
No. In court stipulation responding to ICAN's lawsuit, the CDC identified 20 studies as its complete evidence base for claiming infant vaccines do not cause autism. Zero of those 20 studies examined IPV in the relevant infant age window for autism causation. IPV is given at 2, 4, and 6-18 months — directly during the developmental period in question.
What did the Henry Ford study find about vaccinated vs unvaccinated children?
The Henry Ford study examined 18,468 children comparing vaccinated (full CDC schedule including IPV) and unvaccinated cohorts. Vaccinated children had 2.5 times the overall rate of chronic disease, with significantly higher rates of asthma, autoimmune disease, and neurodevelopmental disorders. Zero ADHD, learning disabilities, tics, or behavioral disabilities were found in unvaccinated children at age 10. Henry Ford Health System administration blocked publication of the study.
Does the IPOL package insert mention deaths after vaccination?
Yes. The FDA-approved IPOL package insert states that "deaths have occurred in temporal association after vaccination of infants." However, because the pre-licensure trial had no control group and only 3 days of monitoring, the insert notes that "no causal relationship has been established." The trial design made any causal investigation structurally impossible — you cannot determine if deaths are elevated without a comparison group.

This is the plain-HTML rendering of vaccines/post-licensure/IPV Vaccines.md, served for search engines, AI crawlers, and accessibility tools. The interactive 3D version of this wiki lives at vaccine-safety.org.